Harvard i-lab: Understanding Reimbursement for Life Sciences Startups

Download IconDownload Print IconPrint

Harvard i-lab: Understanding Reimbursement for Life Sciences Startups

Boston, MA
Speaking Engagement
Being able to answer, "Will my device get reimbursed?" has become critical, even for early development stage life sciences companies. From early investment rounds, investors want assurance of a return on their investment, and while they may not expect startup companies to have all the reimbursement answers, they do expect companies to have identified the correct reimbursement questions. Investors understand that potential provider customers—hospitals and physicians—want to know they can access technologies to advance health care for patients, bill and be paid for their services and preserve their bottom line. Patients play a critical role in decision-making as they weigh their out-of-pocket costs; they want to know if their insurance will cover and pay for treatments.

Importantly, manufacturers need to understand how reimbursement influences access- how payers and providers evaluate clinical and economic evidence supporting the adoption of technology. This presentation will focus on why it is important to create an implementable business strategy that highlights and incorporates obtaining reimbursement and/or defining the value proposition for a product so it can be successfully commercialized in the ever-changing healthcare environment.

Read More About the Event

You May Be Interested In

Managing Cyber Risks in 2024: Regulatory Compliance, Litigation Risk, Third-Party Cybersecurity Incident Exposure

April 24, 2024
Speaking Engagement

PLI's Corporate Governance – A Master Class 2024

April 25, 2024
Speaking Engagement

FIA Law & Compliance Division Conference 2024

April 24–26, 2024
Speaking Engagement
View all Events

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel